Review article: maintenance treatment of Crohn's disease.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 12786610)

Published in Aliment Pharmacol Ther on June 01, 2003

Authors

L Biancone1, C Tosti, D Fina, M Fantini, F De Nigris, A Geremia, F Pallone

Author Affiliations

1: Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università degli Studi di Roma Tor Vergata, Rome, Italy. biancone@med.uniroma2.it

Articles by these authors

Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology (1997) 3.00

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther (2012) 2.89

Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut (1987) 2.44

Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol (1999) 2.38

Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut (1991) 2.21

Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol (2000) 2.08

Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut (2007) 1.98

Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosome. Nat Genet (1995) 1.95

Expression of proinflammatory and Th1 but not Th2 cytokines is enhanced in gastric mucosa of Helicobacter pylori infected children. Dig Liver Dis (2001) 1.77

Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology (1995) 1.74

Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer (2011) 1.73

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology (1992) 1.72

Analysis of the OA1 gene reveals mutations in only one-third of patients with X-linked ocular albinism. Hum Mol Genet (1995) 1.64

Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis (2005) 1.61

Appendectomy is an independent protective factor for ulcerative colitis: results of a multicentre case control study. The Italian Group for the Study of the Colon and Rectum (GISC) Ital J Gastroenterol Hepatol (1997) 1.53

Isotypic analysis of antibody response to a food antigen in inflammatory bowel disease. Int Arch Allergy Appl Immunol (1985) 1.52

Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut (2006) 1.47

Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis (2007) 1.43

Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology (1999) 1.41

Mucosal and systemic antibody levels against Helicobacter pylori do not parallel gastric inflammatory changes. Ital J Gastroenterol Hepatol (1998) 1.37

Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation. J Clin Invest (1996) 1.36

Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology (1995) 1.33

The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol (1988) 1.31

HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol (1987) 1.28

Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis (2001) 1.26

TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol (2008) 1.26

A novel diagnostic tool for detecting functional patency of the small bowel: the Given patency capsule. Endoscopy (2005) 1.26

Immunoregulation in the gut: success and failures in human disease. Gut (2002) 1.25

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2005) 1.25

Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2003) 1.22

Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. Eur J Immunol (1993) 1.22

Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J Clin Invest (1996) 1.22

Multinucleated giant cells generation induced by interferon-gamma. Changes in the expression and distribution of the intercellular adhesion molecule-1 during macrophages fusion and multinucleated giant cell formation. Lab Invest (1994) 1.22

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther (1994) 1.22

Th17-related cytokines in inflammatory bowel diseases: friends or foes? Curr Mol Med (2012) 1.17

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology (1999) 1.17

Gliadin induced changes in the expression of MHC-class II antigens by human small intestinal epithelium. Organ culture studies with coeliac disease mucosa. Gut (1992) 1.16

Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol (2000) 1.13

Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli. Gastroenterology (1989) 1.12

Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology (1998) 1.07

Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J (2000) 1.07

Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther (2009) 1.03

Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology (1999) 1.01

CAD/CAM and rapid prototyped scaffold construction for bone regenerative medicine and surgical transfer of virtual planning: a pilot study. Comput Med Imaging Graph (2008) 1.01

Direct metal laser sintering (DMLS) of a customized titanium mesh for prosthetically guided bone regeneration of atrophic maxillary arches. Med Biol Eng Comput (2011) 0.99

Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ (2006) 0.99

Salivary specific IgG is a sensitive indicator of the humoral immune response to Helicobacter pylori. FEMS Immunol Med Microbiol (1995) 0.98

Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res (1994) 0.98

Seroepidemiology of Helicobacter pylori infection and hepatitis A in a rural area: evidence against a common mode of transmission. Gut (1997) 0.98

Salivary-specific immunoglobulin G in the diagnosis of Helicobacter pylori infection in dyspeptic patients. Am J Gastroenterol (1995) 0.98

In vitro studies on cellular and humoral chemotaxis in Crohn's disease using the under agarose gel technique. Gut (1981) 0.97

Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin (2000) 0.96

Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol (1988) 0.96

Endoscopic vs ultrasonographic findings related to Crohn's disease recurrence: a prospective longitudinal study at 3 years. J Crohns Colitis (2010) 0.96

Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa. Gut (2004) 0.96

Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effects. Neurology (1976) 0.95

Studies of peripheral blood lymphocytes in Crohn's disease. Circulating activated T cells. Scand J Gastroenterol (1983) 0.94

Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis (2001) 0.94

Review article: monitoring the activity of Crohn's disease. Aliment Pharmacol Ther (2002) 0.94

A CAD/CAM-prototyped anatomical condylar prosthesis connected to a custom-made bone plate to support a fibula free flap. Med Biol Eng Comput (2012) 0.92

Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7. Gut (1998) 0.92

Helicobacter pylori infection in children with celiac disease: prevalence and clinicopathologic features. J Pediatr Gastroenterol Nutr (1999) 0.91

Melanosis of the rectum in patients with chronic constipation. Dis Colon Rectum (1985) 0.91

Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci (2000) 0.91

T cell early activation antigens expressed by peripheral lymphocytes in Crohn's disease. J Clin Lab Immunol (1985) 0.90

The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens (2010) 0.89

Isotypic analysis of specific antibody response in serum, saliva, gastric and rectal homogenates of Helicobacter pylori-infected patients. FEMS Immunol Med Microbiol (1995) 0.89

Trastuzumab-related thrombocytopenia: always a self-limiting complication? Ann Oncol (2009) 0.89

Raised serum levels of IgM-rheumatoid factor and anti-F(ab')2 autoantibodies in patients with active inflammatory bowel disease. J Clin Lab Immunol (1986) 0.88

Salivary immunoglobulin G assay to diagnose Helicobacter pylori infection in children. J Clin Microbiol (1997) 0.88

Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice. J Biol Regul Homeost Agents (2013) 0.88

Helicobacter pylori-specific IgG in chronic haemodialysis patients: relationship of hypergastrinaemia to positive serology. Nephrol Dial Transplant (1996) 0.88

Unsedated transnasal versus transoral sedated upper gastrointestinal endoscopy: a one-series prospective study on safety and patient acceptability. Dig Liver Dis (2008) 0.87

Transglutaminases in Crohn's disease. Gut (1995) 0.87

Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin A production by intestinal lamina propria lymphocytes. Gastroenterology (1994) 0.87

Interleukin-25 production is differently regulated by TNF-α and TGF-β1 in the human gut. Mucosal Immunol (2010) 0.86

Solitary juvenile polyp of the stomach. Hum Pathol (1986) 0.86

Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clin Exp Immunol (1998) 0.86

Technetium-99m-HMPAO labeled leukocyte single photon emission computerized tomography (SPECT) for assessing Crohn's disease extent and intestinal infiltration. Am J Gastroenterol (2005) 0.86

Resident bacterial flora and immune system. Dig Liver Dis (2002) 0.86

The biological relevance of polykaryons in the immune response. Immunol Today (1997) 0.86

Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis. Ital J Gastroenterol Hepatol (1998) 0.86

IL-15 positively regulates IL-21 production in celiac disease mucosa. Mucosal Immunol (2012) 0.85

A limiting-dilution analysis of activated circulating B cells in Crohn's disease. J Clin Immunol (1990) 0.85

Frataxin participates to the hypoxia-induced response in tumors. Cell Death Dis (2011) 0.85

Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther (2004) 0.84

A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Aliment Pharmacol Ther (2012) 0.84

Interleukin-23R Arg381Gln is associated with susceptibility to Crohn's disease but not with phenotype in an Italian population. Gastroenterology (2007) 0.84